SI2808340T1 - Rekombinirani FSH, ki vključuje alfa 2,3- in alfa 2,6-sialilacijo - Google Patents

Rekombinirani FSH, ki vključuje alfa 2,3- in alfa 2,6-sialilacijo

Info

Publication number
SI2808340T1
SI2808340T1 SI200931547A SI200931547A SI2808340T1 SI 2808340 T1 SI2808340 T1 SI 2808340T1 SI 200931547 A SI200931547 A SI 200931547A SI 200931547 A SI200931547 A SI 200931547A SI 2808340 T1 SI2808340 T1 SI 2808340T1
Authority
SI
Slovenia
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Application number
SI200931547A
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2808340(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of SI2808340T1 publication Critical patent/SI2808340T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SI200931547A 2008-04-16 2009-04-16 Rekombinirani FSH, ki vključuje alfa 2,3- in alfa 2,6-sialilacijo SI2808340T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
SI2808340T1 true SI2808340T1 (sl) 2016-12-30

Family

ID=39717519

Family Applications (4)

Application Number Title Priority Date Filing Date
SI200931670A SI3045471T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vključuje alfa 2,3 in alfa 2,6-sialilacijo
SI200930931T SI2268666T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vsebuje alfa 2,3- in alfa 2,6-sialilacijo
SI200932094T SI3144318T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vsebuje alfa 2,3- in alfa 2,6-sialilacijo
SI200931547A SI2808340T1 (sl) 2008-04-16 2009-04-16 Rekombinirani FSH, ki vključuje alfa 2,3- in alfa 2,6-sialilacijo

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SI200931670A SI3045471T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vključuje alfa 2,3 in alfa 2,6-sialilacijo
SI200930931T SI2268666T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vsebuje alfa 2,3- in alfa 2,6-sialilacijo
SI200932094T SI3144318T1 (sl) 2008-04-16 2009-04-16 Rekombinantni FSH, ki vsebuje alfa 2,3- in alfa 2,6-sialilacijo

Country Status (29)

Country Link
US (5) US8951967B2 (sl)
EP (7) EP2722339A1 (sl)
JP (7) JP2011519359A (sl)
KR (5) KR20170110741A (sl)
CN (3) CN105906702A (sl)
AR (1) AR071479A1 (sl)
AU (5) AU2009237479B2 (sl)
BR (1) BRPI0910461B8 (sl)
CA (1) CA2725257A1 (sl)
CY (1) CY1115413T1 (sl)
DK (4) DK2268666T3 (sl)
ES (3) ES2468318T3 (sl)
FR (1) FR17C1020I2 (sl)
HK (2) HK1146284A1 (sl)
HR (3) HRP20140535T1 (sl)
HU (5) HUE030652T4 (sl)
IL (2) IL208538A (sl)
LT (5) LT3098234T (sl)
MX (3) MX2010011343A (sl)
NO (2) NO2017025I1 (sl)
NZ (1) NZ588381A (sl)
PL (4) PL2808340T3 (sl)
PT (4) PT2268666E (sl)
RU (3) RU2682270C2 (sl)
SA (1) SA109300228B1 (sl)
SI (4) SI3045471T1 (sl)
TW (1) TWI488640B (sl)
WO (1) WO2009127826A1 (sl)
ZA (1) ZA201007373B (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
EP2628797B1 (en) 2010-10-15 2016-07-13 JCR Pharmaceuticals CO., LTD. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
EP2691119B1 (en) 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
US9657310B2 (en) * 2012-04-27 2017-05-23 Jcr Pharmaceuticals Co., Ltd. Expression vector
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Jcrファーマ株式会社 ウリジンとn−アセチル−d−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Cmp依存性シアリダーゼ活性
ES2784625T3 (es) 2015-04-17 2020-09-29 Ferring Bv FSH para el tratamiento de la infertilidad
AU2016282916B2 (en) * 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
PT3675894T (pt) 2017-09-01 2022-01-25 Ferring Bv Composição para estimulação ovariana controlada
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
MX2021004383A (es) 2018-10-17 2021-06-04 Ferring Bv Composiciones y metodos para la estimulacion ovarica controlada.
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
ES2218806T3 (es) 1997-01-16 2004-11-16 Neose Technologies, Inc. Sialilacion practica in vitro de glicoproteinas recombinantes.
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
US7695721B1 (en) 1999-05-07 2010-04-13 Merck Serono S.A. Gonadotrophins in the treatment anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EA007030B1 (ru) * 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Гонадотропины для фолликулогенеза
JP4583029B2 (ja) 2001-10-29 2010-11-17 クルセル ホランド ベー ヴェー 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段
AU2002351444B2 (en) 2001-12-07 2008-02-21 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
WO2005076013A2 (en) 2004-02-04 2005-08-18 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
WO2005080585A1 (en) 2004-02-13 2005-09-01 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
EP2691119B1 (en) 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
JP2017513853A (ja) 2014-04-18 2017-06-01 グリコトープ ゲーエムベーハー 改良された組換えヒト卵胞刺激ホルモンを用いた制御された卵巣過剰刺激

Also Published As

Publication number Publication date
IL208538A (en) 2014-03-31
RU2745557C3 (ru) 2021-12-10
RU2014141994A (ru) 2016-05-10
JP2017060476A (ja) 2017-03-30
SA109300228B1 (ar) 2014-04-08
ZA201007373B (en) 2011-06-29
US20210332099A1 (en) 2021-10-28
EP2808340A1 (en) 2014-12-03
US9546204B2 (en) 2017-01-17
AU2017204258A1 (en) 2017-07-20
SI3045471T1 (sl) 2017-07-31
PL3144318T3 (pl) 2021-02-08
TWI488640B (zh) 2015-06-21
AU2014203277B2 (en) 2017-04-06
PT3045471T (pt) 2017-06-14
EP2808340B1 (en) 2016-08-17
WO2009127826A1 (en) 2009-10-22
US20160347811A1 (en) 2016-12-01
KR20190092608A (ko) 2019-08-07
MX2010011343A (es) 2011-01-20
DK3045471T3 (en) 2017-06-26
KR101622944B1 (ko) 2016-05-23
EP3045471A1 (en) 2016-07-20
LT2808340T (lt) 2016-11-10
EP4015527A1 (en) 2022-06-22
CN102066414A (zh) 2011-05-18
RU2014141994A3 (sl) 2018-05-28
AR071479A1 (es) 2010-06-23
JP6762916B2 (ja) 2020-09-30
EP2722339A1 (en) 2014-04-23
SI2268666T1 (sl) 2014-07-31
KR20160056960A (ko) 2016-05-20
DK2268666T3 (da) 2014-05-12
RU2537268C2 (ru) 2014-12-27
AU2014203277C1 (en) 2017-07-27
HUE030652T4 (en) 2017-09-28
KR20170110741A (ko) 2017-10-11
US11952407B2 (en) 2024-04-09
AU2017204259B2 (en) 2017-08-17
NO2017025I1 (no) 2017-06-06
BRPI0910461B1 (pt) 2021-02-23
JP6486310B2 (ja) 2019-03-20
AU2017204259A1 (en) 2017-07-20
PT2808340T (pt) 2016-11-21
EP3098234A1 (en) 2016-11-30
US20180079794A1 (en) 2018-03-22
HUS1700024I1 (hu) 2017-06-28
JP2011519359A (ja) 2011-07-07
NZ588381A (en) 2012-05-25
HK1146284A1 (en) 2011-05-20
PL2268666T3 (pl) 2014-08-29
CN105906702A (zh) 2016-08-31
JP2018021037A (ja) 2018-02-08
HK1199039A1 (en) 2015-06-19
NO2017050I1 (no) 2017-09-28
LT3098234T (lt) 2024-09-10
PL3045471T3 (pl) 2017-10-31
HRP20170958T1 (hr) 2017-09-22
US20150065695A1 (en) 2015-03-05
EP3144318B1 (en) 2020-09-23
US10995128B2 (en) 2021-05-04
CN105906703A (zh) 2016-08-31
LTPA2017018I1 (lt) 2017-06-26
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HUE030652T2 (en) 2017-05-29
EP2268666B1 (en) 2014-03-12
TW200948378A (en) 2009-12-01
ES2629392T3 (es) 2017-08-09
AU2017225020A1 (en) 2017-09-28
US8951967B2 (en) 2015-02-10
MX348622B (es) 2017-06-22
CY1115413T1 (el) 2017-01-04
AU2017204258B2 (en) 2017-08-17
LT3045471T (lt) 2017-07-10
LTPA2017029I1 (lt) 2017-10-10
IL208538A0 (en) 2010-12-30
AU2014203277A1 (en) 2014-07-24
HRP20161520T1 (hr) 2016-12-30
RU2682270C2 (ru) 2019-03-18
JP2022031652A (ja) 2022-02-22
DK3144318T3 (da) 2020-12-07
KR20110005863A (ko) 2011-01-19
KR102108377B1 (ko) 2020-05-08
CA2725257A1 (en) 2009-10-22
AU2009237479A1 (en) 2009-10-22
AU2009237479B2 (en) 2014-05-15
PT3144318T (pt) 2020-11-04
EP2268666A1 (en) 2011-01-05
DK2808340T3 (en) 2016-12-05
KR20180095140A (ko) 2018-08-24
ES2468318T3 (es) 2014-06-16
EP3045471B1 (en) 2017-03-29
RU2010141908A (ru) 2012-05-27
FR17C1020I2 (fr) 2020-04-10
JP2024038000A (ja) 2024-03-19
EP3144318A1 (en) 2017-03-22
PL2808340T3 (pl) 2017-02-28
EP3098234B1 (en) 2024-07-31
IL230571A (en) 2015-11-30
AU2017225020B2 (en) 2019-11-14
HUS1700025I1 (hu) 2017-06-28
SI3144318T1 (sl) 2020-12-31
BRPI0910461A8 (pt) 2018-10-16
RU2745557C1 (ru) 2021-03-29
HUS1700036I1 (hu) 2017-10-30
PT2268666E (pt) 2014-06-25
JP7316905B2 (ja) 2023-07-28
BRPI0910461A2 (pt) 2018-03-27
US9771407B2 (en) 2017-09-26
JP2015120696A (ja) 2015-07-02
FR17C1020I1 (sl) 2020-04-10
HUE033830T2 (en) 2018-01-29
MX355457B (es) 2018-04-19
JP2020040956A (ja) 2020-03-19
US20110105398A1 (en) 2011-05-05
BRPI0910461B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HUS1700036I1 (hu) Rekombináns, alfa-2,3- és alfa-2,6-szializációt tartalmazó FSH
EP2344648A4 (en) RECOMBINANT VECTORS
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
AP2010005388A0 (en) Pupicidal and larvicidal composition.
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
IL207174A0 (en) Peptides, compositions, and uses thereof
LT3144318T (lt) Rekombinantinis fsh, įskaitant alfa-2,3- ir alfa-2,6-sialilinimą
GB0715213D0 (en) Igf-1
EP2384338A4 (en) GLP-1 ANALOGS AND THEIR APPLICATIONS
GB0808401D0 (en) Fsh
GB0813815D0 (en) Corcost Pre 1001,10
GB0809709D0 (en) Dunhill car,2093
GB0705503D0 (en) The buffer
GB0808811D0 (en) Algabe 2.1
GB0717996D0 (en) Composites
GB0808846D0 (en) 10000002
GB0807658D0 (en) Sebaforce 2
GB0808845D0 (en) 10000003